Legend Biotech (LEGN) Stock Price, Financials & Analysis

Key Stats

Market Cap3.44 Bn

P/E-37.48

P/S2.70

Div. Yield0.00

Total Debt (Qtr)156.40 Mn

Revenue Growth (1y) (Qtr)51.90

Add ratio to table…

About

Legend Biotech Corporation is a global biopharmaceutical company focused on the discovery development manufacturing and commercialization of novel cell therapies for oncology and other indications. The company leverages its proprietary technology and integrated capabilities to advance product candidates from research through clinical testing to market. Legend Biotech Corporation generates revenue primarily from the sale of its approved CAR T therapy CARVYKTI which treats…

How Legend Biotech ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −38.2xMedian 16.8x 82^nd
P/FCFNegative free cash flow −54.2xMedian 18.3x 81^st
P/Operating cash flowNegative operating cash flow −39.2xMedian 17.0x 78^th
P/S 2.76xMedian 9.38x 74^th
P/B 2.85xMedian 2.17x 41^st
P/Tangible book 2.85xMedian 2.42x 44^th
EV/EBITDANegative EBITDA −162xMedian 15.7x 78^th
EV/EBITNegative EBIT −54.1xMedian 19.8x 80^th
EV/Revenue 2.35xMedian 6.59x 74^th
EV/FCFNegative free cash flow −46.2xMedian 19.2x 77^th
EV/Operating cash flowNegative operating cash flow −33.4xMedian 16.0x 73^rd
PEG (3Y EPS CAGR)Negative earnings −0.81Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 59.5%Median 10.2% 74^th
Revenue CAGR (3Y) 97.6%Median 10.2% 88^th
Gross profit growth (1Y) 42.4%Median 10.6% 74^th
Gross profit CAGR (3Y) 148%Median 10.7% 95^th
Operating income growth (1Y) 75.3%Median 0.0% 91^st
Operating income CAGR (3Y) −32.1%Median 1.6% 16^th
Net income growth (1Y) 75.3%Median −5.1% 90^th
Net income CAGR (3Y) 46.7%Median −0.4% 91^st
EPS growth (1Y) 72.0%Median 21.0% 79^th
EPS CAGR (3Y) 47.0%Median 25.3% 74^th
Operating cash flow growth (1Y) 67.5%Median 0.3% 90^th
Operating cash flow CAGR (3Y) 37.1%Median 2.4% 88^th
Free cash flow growth (1Y) 77.8%Median 0.3% 91^st
Free cash flow CAGR (3Y) 44.5%Median 3.3% 92^nd

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 57.2%Median 74.0% 30^th
EBITDA margin −1.5%Median −216% 75^th
Operating margin −4.3%Median −230% 76^th
Pretax margin −4.4%Median −223% 77^th
Net margin −7.2%Median −230% 75^th
FCF margin −5.1%Median −168% 72^nd
Operating cash flow margin −7.0%Median −157% 70^th
Return on equity −8.3%Median −53.5% 81^st
Return on assets −5.5%Median −42.0% 82^nd
Return on invested capital −4.2%Median −5.3% 51^st
Return on capital employed −4.3%Median −46.0% 83^rd
Asset turnover 0.76xMedian 0.18x 87^th
Cash conversion (OCF / net income)Net income is not positive 1.11xMedian 1.21x Not meaningful —
Stock comp / revenue 5.2%Median 27.5% 81^st

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 8.9%Median 20.0% 68^th
Debt / equity 0.13xMedian 0.26x 66^th
Net debt / EBITDAEBITDA is not positive 28.0xMedian 1.82x Not meaningful —
Debt / FCFFree cash flow is not positive −2.42xMedian 3.03x Not meaningful —
Liabilities / assets 29.8%Median 32.8% 53^rd
Equity / assets 70.2%Median 67.2% 53^rd
Interest coverage −4.83xMedian −10.1x 61^st
Current ratio 3.04xMedian 4.48x 38^th
Quick ratio 1.67xMedian 3.72x 31^st
Cash ratio 1.67xMedian 3.34x 35^th
Altman Z-score 6.20Median −0.62 79^th

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,134.50 Bn	42.47	14.24	54.91 Bn
2	JNJ	Johnson & Johnson	616.20 Bn	29.29	6.29	49.04 Bn
3	ABBV	AbbVie Inc.	500.82 Bn	79.37	7.78	70.82 Bn
4	MRK	Merck & Co., Inc.	367.31 Bn	115.76	5.52	53.91 Bn
5	NVS	Novartis Ag	297.77 Bn	18.88	5.44	9.59 Bn
6	AZN	Astrazeneca Plc	261.35 Bn	25.02	4.45	32.35 Bn
7	AMGN	Amgen Inc	235.40 Bn	26.92	6.18	57.30 Bn
8	LEGN	Legend Biotech Corp	3.44 Bn	-37.48	2.70	0.16 Bn

Legend Biotech LEGN

About

Geographical Breakdown of Revenue (2024)

Counterparties [axis] Breakdown of Revenue (2024)

How Legend Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Legend Biotech LEGN

About

Geographical Breakdown of Revenue (2024)

Counterparties [axis] Breakdown of Revenue (2024)

How Legend Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password